Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VanEck Pharmaceutical ETF (NQ:PPH)

111.14 +0.28 (+0.25%)
Streaming Delayed Price Updated: 10:22 AM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VanEck Pharmaceutical ETF

< Previous 1 2 3 Next >
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
News headline image
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? ↗
PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee. 
Via The Motley Fool
Topics ETFs
News headline image
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The... 
Via The Motley Fool
Topics ETFs
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
Via Stocktwits
KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗
Via Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
News headline image
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential. 
Via The Motley Fool
Topics ETFs
News headline image
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy? ↗
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals. 
Via The Motley Fool
Topics ETFs
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗
The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary. 
Via Stocktwits
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products. 
Via Stocktwits
News headline image
Why Did GERN Stock Tumble 10% Pre-Market Today? ↗
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China. 
Via Stocktwits
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead. 
Via Stocktwits
Topics Intellectual Property
News headline image
Why Is NVO Stock Falling Pre-Market Today? ↗
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint. 
Via Stocktwits
Topics Government
News headline image
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. 
Via Stocktwits
Topics Lawsuit
News headline image
Why Did IINN Stock Surge 28% In Pre-Market Today? ↗
The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members. 
Via Stocktwits
News headline image
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
Via Stocktwits
Topics World Trade
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize. 
Via Benzinga
Topics ETFs
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
Via Benzinga
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet ↗
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure. 
Via Benzinga
Topics ETFs Government
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.